Investigation of Rational Use and Regulation of Traditional Chinese Medicine Injections Based on the Utility Analysis of Our Hospital from 2012 to 2014
LIU Zhi-jun,CHEN Di, TAN Ling
Department of Pharmacy, Beijing Hospital, Beijing 100730, China
Abstract��OBJECTIVE To discuss the methods for clinical rational use and state regulation of high risk Traditional Chinese Medicine Injections (TCMIs) based on our hospital TCMIs analysis and literature review. METHODS By analyzing the prescription rates and amount percentage of TCMIs in emergency, outpatient and inpatient departments of our hospital as well as literature searching to learn the current state and conditions of TCMIs. RESULTS Utilities of TCMIs from 2012 to 2014 shows an elevated tendency with percentages of 1.19%, 1.34% and 1.40% respectively. Emergency, ENT and internal neurology departments of outpatient are the top 3 on prescription rates and amount percentage. Inpatients�� order rates of TCMIs are 0.79%, 0.80% and 0.79% respectively. Oncology (20%-26%), emergency (12%-14%) and internal neurology (10%-11%) departments are the top 3 amount rates in ordering TCMIs,however, the department of TCM only account for 4%-5%. The percentages of TMCIs amount vs. annual total drug amount during 2012-2014 are 2.10%, 2.07% and 2.14%, which is lower than literature reports. CONCLUSION Not all the TCMIs use in our hospital are rational, mainly reflects in non-TCM doctors having used the most amount of TCMIs. Therefore, the TCM consultation policy should be established to support TCMI rational utility, TCMIs labels should be strictly regulated and the quality standards of TCMIs should be elevated to ensure the safety and effectiveness. All above efforts should be done to protect and develop TCMI, an innovation of TCM.
���ξ�,���E,̷��. ����ijԺ2012~2014�����ҩע����ٴ�Ӧ�����̽����ҩע����ĺ���Ӧ�úͼ��[J]. �й�ҩѧ��־, 2015, 50(18): 1648-1652.
LIU Zhi-jun,CHEN Di, TAN Ling. Investigation of Rational Use and Regulation of Traditional Chinese Medicine Injections Based on the Utility Analysis of Our Hospital from 2012 to 2014. Chinese Pharmaceutical Journal, 2015, 50(18): 1648-1652.
YIN ZP, LI L,FANG Z H. Analysis of Traditional Chinese Medicine Injections Rational Use in Emergency and outpatient departments[J]. Chin Pharm Aff (�й�ҩ��), 2014,28(5):566-568.
[2]
SHI DD. The Irrational Use of Traditional Chinese Medicine Injections and Clinical Management[J]. J North Pharm(����ҩѧ), 2014,11(3):39-40.
[3]
WU Y, DING S Q, FANG W L, et al. Utility Analysis of Traditional Chinese Medicine Injections from 2008 to 2012 of certain hospital[J]. China Pharm(�й�ҩҵ),2014,23(1):42-43.
[4]
YIN J, DENG G M. Utilization of Traditional Chinese Medicine Injections in The Inpatients of A Hospital During 2010-2012[J]. Chin J Mod Drug Appl(�й��ִ�ҩ��Ӧ��).2014,8(2):233-235.
[5]
XIONG X J. Analyzing the main problems and reasons of increase in medical costs. [EB/OL].[2015-03-01].http://www.zgylbx.com/yfubucjsnew37172_1/
[6]
ZHOU C F, XU Z L, LIN Y H. Retrospect and prospect of Traditional Chinese Medicine Injections [J].China J Chin Mater Med(�й���ҩ��־),2006,31(24):2094-2096.
[7]
LIU Z, LIU Z Y, WANG X Y. Discussion on the syndrome differentiation application of TCM injection [J]. Clin J Chin Med(��ҽ�ٴ��о�), 2013,5(17):35.
[8]
CFDA. National Adverse Drug Reaction Monitoring Annual Reports (2013)[EB/OL].[2015-03-01]. http://www.sda.gov.cn/WS01/CL0078/99794.html
[9]
CFDA. Announcement of suspend for use and approval Yuxiongcao injections and other 6 injections.[EB/OL].[2015-03-01]. http://www.sda.gov.cn/WS01/CL0087/14804.html
[10]
WANG Y, LIU X H. Introduction of Adverse drug interactions of Traditional Chinese Medicine Injections[J]. Chin Pharm J (�й�ҩѧ��־), 2007,42(8):633-635.
[11]
XIAO X, FU C, LIANG J L, et al. determination of proteinoid fragments in Traditional Chinese Medicine Injections[J]. Chin Pharm J (�й�ҩѧ��־),2012,47( 21):1768-1969.
2015, Vol. 50 
